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Since the advent of nanotechnology in cancer therapeutics, silica nanoparticles have been 
worked upon to improve features such as loading capacity and targetedness, and to 
expand the range of payload that the particles can deliver to target cells. In this project, 
we synthesized pristine mesoporous silica nanoparticles (MSN) and functionalised these 
with phosphonate groups (MSN-Phos) towards building a robust system suited for 
loading and delivery of the hydrophilic anti-cancer drug Doxorubicin hydrochloride 
(DOX). Negatively charged phosphonate groups were selected to modify the MSN 
surface for improved association with positively charged DOX molecules.  
Synthesized nanoparticles fall within a size range of 50-350nm, with specific surface area 
of 256m
2
/g in pristine MSN and 86 m
2
/g in phosphonate functionalised MSN. Despite a 
lower surface area of MSN-Phos, these particles recorded 0.39mg DOX/m
2
 of 
nanoparticle compared to 0.28mg DOX/m
2
 in pristine MSN, suggesting successful 
application of surface functionalisation towards improved loading efficiency of MSN. 
This project reports, for the first time, cell death in MCF-7 cells (human breast 
adenocarcinoma cell line) when treated with unloaded MSN and unloaded MSN-Phos. 
The same nanoparticles were found to elicit few deleterious effects on normal human 
foreskin fibroblast cells (BJ cells). This project concludes that a 24 h exposure to these 
nanoparticles led to a concentration-dependent uptake in the MCF-7 cells while no 
detectable uptake was observed in the BJ cells, irrespective of treatment dosage. We 
determined a disruption of the cell cycle in the MCF-7 cells to be the cause of cell death 
from the nanoparticle exposure, thereby suggesting the role of non-drug loaded 
phosphonate functionalized MSN as an effective anti-cancer drug in itself.  
vi 
 
LIST OF TABLES 
TABLE 1 –  SEQUENCE OF QPCR PRIMERS SCREENED IN THE CELL CYCLE 
ANALYSIS                17  
 
TABLE 2 –  SUMMARY OF THE AVERAGE PORE DIAMETER, TOTAL PORE 
VOLUME AND SPECIFIC SURFACE AREA OF DIFFERENT 
NANOPARTICLES               21 
 
TABLE 3 –  AVERAGE PORE DIAMETERS AND DOX LOADING 
EFFICIENCIES OF NANOPARTICLES           24 
 




LIST OF FIGURES 
SCHEMATIC 1 – MECHANISM OF FORMATION OF MESOPOROUS SILICA 
NANOPARTICLES BY MICELLE-TEMPLATING 
METHOD                                 11 
 
SCHEMATIC 2 –  PROPOSED REACTION SEQUENCE OF NABH4 
CHEMICAL ETCHING TO INCREASE MSN PORE SIZE. IN 
(1) CHEMICAL INTERACTION OF NABH4 AND H2O 
PRODUCED NABO2 AND H2 CREATING AN ALKALINE 
CONDITION THAT CAUSED THE Si-O BONDS TO BREAK 
REVERSIBLY AND INCREASED PORE SIZE          13 
 
FIG. 1 – TEM IMAGES OF (A) MSN, (B) MSN-E, (C) MSN-PHOS AND (D) MSN-
PHOS-E WERE ANALYZED TO DETERMINE RESPECTIVE PRIMARY 
PARTICLE SIZES. DATA REPRESENTS MEAN ± SD, N=3. SCALE BAR = 
50NM                  18 
 
FIG. 2 – HYDRODYNAMIC RADIUS (A) AND ZETA-POTENTIAL (B) OF THE 
NANOPARTICLES BEFORE AND AFTER ETCHING; THE 
NANOPARTICLES WERE MEASURED IN DMEM COMPLETE MEDIA. 
DATA REPRESENTS MEAN ± SD, N=3            19 
 
FIG. 3 – PORE SIZE DISTRIBUTION AS OBTAINED FROM BJH ANALYSIS 
METHOD OF (A) MSN, (B) MSN-E, (C) MSN-PHOS AND(D) MSN-PHOS-E 
(INSET DEPICTS RESPECTIVE ADSORPTION-DESORPTION 
ISOTHERMS)                20  
 
FIG. 4 – FTIR ANALYSIS DEPICTED COMPLETE REMOVAL OF SURFACTANT 
CTAC MOLECULES FROM THE SYNTHESIZED NANOPARTICLES 
(FIG.1A AND 1B) POST-CALCINATION (C-H STRETCHING PEAKS 
BETWEEN 2950 AND 2850CM
-1
 AS INDICATED BY THE RECTANGULAR 
BOX); P=O PEAKS BETWEEN 1260 AND 1230CM
-1
 IN FIG. 1B SHOWED 
SUCCESSFUL PHOSPHONATE GROUP FUNCTIONALISATION OF THE 
NANOPARTICLES                22  
 
FIG. 5 – XPS SPECTRA OF MSN-E (A-C) AND MSN-PHOS-E (D-F) SHOWED 
PRESENCE OF SI2P AND O1S PEAKS IN MSN-E AND THOSE FOR SI2P, 




FIG. 6 – THE FIGURES PRESENT CELL VIABILITY OF MCF-7 (A) AND BJ 
CELLS (B) AGAINST A CONCENTRATION DEPENDENT SCENARIO OF 
NANOPARTICLE TREATMENT AND THE SAME FOR MCF-7 AND BJ 
CELLS AGAINST A TIME DEPENDENT SCENARIO (C, D). DATA 
REPRESENTS MEAN ± SD, N=3, *P<0.05 VERSUS CONTROL          27 
 
FIG. 7 – QUALITATIVE STUDY OF NANOPARTICLE UPTAKE USING 
CONFOCAL LASER SCANNING MICROSCOPE (CLSM) OF MCF-7 AND 
BJ CELLS WHEN TREATED WITH 250µG/ML OF FITC-TAGGED MSN-E 
AND MSN-PHOS-E FOR 24 H SHOWED SIGNIFICANT UPTAKE BY MCF-
7 CELLS IN COMPARISON TO A CLOSE-TO-NIL UPTAKE SHOWN BY BJ 
CELLS                  28 
 
FIG. 8 – QUANTITATIVE STUDY OF NANOPARTICLE UPTAKE USING ICP-MS 
UPON TREATMENT OF MCF-7 AND BJ CELLS WITH VARYING 
CONCENTRATIONS OF NANOPARTICLES FOR 24 H SHOWED A 
CONCENTRATION DEPENDENT UPTAKE OF NANOPARTICLES BY THE  
MCF-7 CELLS WHEREAS SI WAS NOT DETECTED (ND) IN THE BJ 
CELLS INDICATING POOR UPTAKE BY THESE CELLS. DATA 
REPRESENTS MEAN ± SD, N=3              29  
 
FIG. 9 – QPCR ANALYSIS OF MCF-7 AND BJ CELLS TREATED WITH 250UG/ML 
OF NANOPARTICLES FOR 48 H (A) VERSUS 72 H (B) INDICATED THAT 
DETERIORATION IN CELL NUMBERS OBSERVED CAN BE 
ATTRIBUTED TO IRREGULARITIES IN THE CELL CYCLE OF THE 
CELLS. THE ABSENCE OF ANY SIGNIFICANT UP-REGULATION IN 
BAX AND TNFRSF1A GENES INDICATED NO ROLE OF APOPTOSIS IN 
CAUSING ANY CELL DEATH              30  
 
FIG. 10 – MCF-7 AND BJ CELLS WERE SYNCHRONISED IN THE G0/G1 PHASE 
(A) AND UPON TREATMENT WITH MSN-E AND MSN-PHOS-E FOR 48 H 
MCF-7 CELLS SHOWED AN INCREASE IN CELL POPULATION IN THE 
G2/M PHASE INDICATING CELL CYCLE ARREST, WHILE A DECREASE 
IN THE SAME WITH THE BJ CELLS INDICATED NO EFFECT OF THE 
NANOPARTICLE TREATMENT ON THE CELL CYCLE FOR THESE 
CELLS. DATA REPRESENTS MEAN ± SD, N=3            33  
ix 
 
LIST OF SYMBOLS AND ABBREVIATIONS 
%   PERCENTAGE 
±   PLUS MINUS SIGN 
⁰C   DEGREE CELSIUS 
µ   MICRO 
Å   ANGSTROM 
nm   NANOMETER 
APTES   (3-AMINOPROPYL)TRIETHOXYSILANE 
ATCC   AMERICAN TYPE CULTURE COLLECTION 
ATM   ATAXIA TELANGIECTASIA MUTATED 
Bcl-2   B-CELL LYMPHOMA 2 
BET   BRUNAUER-EMMETT-TELLER 
BJH   BARRETT-JOYNER-HALENDA 
BSA   BOVINE SERUM ALBUMIN 
CDK1   CYCLIN DEPENDENT KINASE 1 
CLSM   CONFOCAL LASER SCANNING MICROSCOPE 
CTAC   CETRYLTRIMETHYLAMMONIUM CHLORIDE 
DLS   DYNAMIC LIGHT SCATTERING 
DMEM   DULBECCO’S MODIFIED EAGLE’S MEDIUM 
DMSO   DIMETHYL SULFOXIDE 
DOX   DOXORUBICIN HYDROCHLORIDE 
FBS   FETAL BOVINE SERUM 
FITC   FLUORESCEIN ISOTHIOCYANATE 
FTIR   FOURIER TRANSFORM INFRARED SPECTROSCOPY 
GAPDH  GLYCERALDEHYDE 3-PHOSPHATE DEHYDROGENASE 
ICP-MS  INDUCTIVELY COUPLED PLASMA MASS 
SPECTROMETRY 
MSN   MESOPOROUS SILICA NANOPARTICLE 
MSN-E   CALCINATED AND ETCHED MESOPOROUS SILICA 
NANOPARTICLE 
MSN-Phos PHOSPHONATE GROUP FUNCTIONALISED 
MESOPOROUS SILICA NANOPARTICLE 
MSN-Phos-E CALCINATED AND ETCHED PHOSPHONATE GROUP 
FUNCTIONALISED MESOPOROUS SILICA 
NANOPARTICLE 
MSN-Phos-pristine AS-SYNTHESIZED PHOSPHONATE GROUP 
FUNCTIONALISED MESOPOROUS SILICA 
NANOPARTICLE 
MSN-pristine AS-SYNTHESIZED MESOPOROUS SILICA 
NANOPARTICLE 
MTT 3-(4,5- DIMETHYLTHIAZOL-2-YL)-2,5-DIPHENYL 
TETRAZOLIUM BROMIDE 
ND NOT DETECTED 
NIR NEAR-INFRARED 
P< P SMALLER THAN 
PBS PHOSPHATE BUFFERED SALINE 
PFA PARAFORMALDEHYDE 
RPM REVOLUTIONS PER MINUTE 
SD STANDARD DEVIATION 
TEM TRANSMISSION ELECTRON MICROSCOPE 
x 
 
TEOS TETRAETHYL ORTHOSILICATE 









1.  REVIEW 
1.1  PROBLEM STATEMENT 
Cancer is one of the world’s leading causes of death. Of the several types of 
cancer, breast cancer ranks among the top few to affect women worldwide; of the 
total estimated 810,170 new cases of cancer to be reported in the US this year, a 
massive 231,840 (over 70%) are expected to belong to breast cancer category
1
. 
In view of the severity of breast cancer and understanding the significance of 
making available better modes of drug administration, this project aimed to 
engineer a system of mesoporous silica anti-breast cancer ‘nanovehicles’ with 
suitable features such as appropriate pore diameter and pore volume for 
optimized drug loading capacity, and ideal particle size for cellular uptake.  
One of the major challenges in designing nanovehicles is the lack of cell-
specificity of these carriers
2,3
. In this project we synthesized mesoporous silica 
nanoparticles with high drug loading efficiencies and demonstrated an inherent 
specificity of these nanoparticles towards tumor cells as opposed to normal cells, 
suggesting a great potential in anti-cancer drug delivery. 
 
1.2 RATIONALE FOR USING DRUG DELIVERY SYSTEMS 
Typically, breast cancer treatment involves surgery followed by chemotherapy, 
hormone therapy or radiotherapy. Once administered, drugs encounter several 
barriers, either in the form of highly acidic tumor microenvironment that can 
affect the structure and/or functioning of the drug or in the form of the reticulo-





. Physical barriers like the nuclear membrane and development for 
multiple drug resistance by the tumor cells are two other hurdles faced by free 
drugs
4
. Several important anti-cancer drugs are hydrophobic in nature and their 
low solubility in aqueous media makes it a herculean task to administer these 
intravenously
5
. All of these factors call for a drug delivery system that can 
overcome the physical barriers, while protecting the cargo drug molecules from 
degradation, and deliver these drug molecules to the tumor cells without causing 
any damage to the surrounding normal cells. 
 
1.2.1  NANOMATERIALS AND THEIR APPLICATIONS IN THE 
BIOMEDICAL FIELD 
An efficient drug delivery system would not just target the tumor cells 
specifically, but also ensure its cargo drug molecules do not release prematurely, 
outside the tumor tissue. Nanomaterials (materials comprising of nanoparticles 
that have a size range of 1-100nm
6-8
) meet the size threshold that favors cellular 
uptake
9-11
. Nanomaterials are also endowed with several useful properties like 
quantum size effects and high surface-to-volume ratio
12,13
. This allows for wide-
spread application of nanomaterials in biomedical applications, in both categories 
of diagnostics and therapeutics. Superparamagnetism of nanomaterials finds its 
application in the form of contrast agents for magnetic resonance imaging 
(MRI)
14-16
, and plasmonic properties are put to use in the form of gold 





 and as contrast agents for immunostaining
20
. Polymer-drug conjugates 
present a water-soluble, biodegradable, tumor targeting drug delivery system that 





dendrimers offer multifunctionality and tunable biodistribution
26, 27
, polymeric 
micelles formed of a hydrophobic core and hydrophilic shell offer easy 
functional modification, are self-assembling and biodegradable
28-30
. 
Liposomes, as opposed to polymeric micelles are self-assembling colloidal 
structures made of lipid bilayers
31
. These too are amphiphilic, biocompatible and 
offer potential targeting functionality
32-34
. Several inorganic materials have been 
used to develop drug delivery systems. Carbon nanotubes form an elegant 
member of this group, with features such as water solubility and physical 
multifunctionality
35,36
. Since these nanotubes have the tendency to bundle 
together in different ways, they exhibit a variety of forms in physiological 
environment thereby benefitting from high surface-to-volume ratios
37
. Graphene 
quantum dots (GQDs) have been labeled with human serum albumin to develop a 
pancreatic cancer specific drug delivery system that had superior bioavailability 
and excellent bioimaging qualities
38
. Another study successfully linked 
luminescent semiconductor quantum dots-encapsulated triblock copolymers to 
tumor targeting ligands and drug delivery functionalities thereby creating a 
multifunctional drug delivery system
39
. Semiconductor quantum dots also are 






1.3  MESOPOROUS SILICA AS NANOCARRIERS 
In the genre of inorganic nanoparticles, mesoporous silica nanoparticles (MSNs) 
have made their mark as one of the favorites. Since their discovery in 1992 by 
Mobil Corporation, extensive research has been conducted on this material 
giving rise to several new forms, from different synthesis techniques
40
. Tunable 
sizes, high surface area, adjustable pore diameters and pore volumes, strong 
physical and thermal stability, optical transparency and easy functionalisation of 
MSNs make these a member of the elite class of drug delivery systems
40-42
. The 
qualities enable MSNs to overcome various biological barriers stated above and 




1.3.1  DOX – THE ANTI-BREAST CANCER DRUG 
Doxorubicin (DOX, trade name Adriamycin
43
) is an established anticancer drug 
that belongs to the class Anthracycline
44
). Anthracyclines are reported to have 
multiple damaging effects on cellular components, and these are assumed to be 
the causative factors for the anti-cancer effects of DOX
44
. Mechanisms of action 
reported include inhibition of DNA and RNA polymerases
45
, alkylation of 
DNA
46
, intercalation with DNA
44
 and intercalation with topoisomerase II
47
. Other 




 and generation 






1.3.2 FUNCTIONALISATION OF MSN FOR IMPROVED DOX DELIVERY 
While DOX has several capabilities that make it a good choice for anti-cancer 
treatment
53-58
, it must be noted that as a free drug DOX is hydrophobic in nature
59
. 
Hence, to treat breast cancer, DOX is administered intravenously in combination 
with two other hydrophilic anti-breast cancer drugs cyclophosphamide (trade 
name Cytoxan) and 5-fluorouracil (5-FU)
43
. This combination of free drugs 
introduced into the patient becomes a cause for severe side-effects since the 
drugs are administered systemically and thus do not target tumor cells 
specifically. Their cytotoxic effects hit both the tumor cells and the more 
sensitive normal cells. To overcome this issue of drug non-specificity and 
thereby effectively reduce the dose of drugs administered to patients, drug 
delivery systems laden with targeting capabilities can deliver the toxic cargo only 
to the tumor cells while sparing the normal cells. 
MSNs with their nano-scale particle size and high surface area to volume ratio 
are an ideal candidate for anti-breast cancer drug delivery to tumor cells. These 
features also enable MSNs to bear multiple functionalities that can be applied to 
improve loading capacity, targetedness, or used for bioimaging purposes
12
. MSN 
functionalities can be classified based on the type of trigger mechanism applied 
to the system
60
. One classification uses molecular groups to block the mesopore 
openings thereby protecting the cargo molecules
61-63
. The macromolecules used 
to block the mesopores are either degradable or linked to the MSN surface via 
linkers that can be cleaved when exposed to a specific stimulus
64,65
. A second 
category uses oligonucleotides, polymers or lipid bilayers to coat the surface of a 
loaded MSN; in this case the trigger is usually a phase transition or competitive 
displacement reactions
66-77
.  And another category uses coordinate or covalent 
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bond to bind the cargo molecules on to the pore walls of the MSN
78-80
 which are 
cleaved by stimuli such as UV or NIR radiations
81-86
 or acidic pH
87-90
, structural 
destabilization caused by hydrophobic-hydrophilic transitions in combination 
with hydrogen bond breaking
91
 or chemical etching of the MSN pores
92
.  
Over the years, researchers have changed their perspective of modifying MSN to 
achieve just optimal drug loading efficiency, controlled release profiles and 
tumor-specificity. The synthesis of a (PEG)-modified doxorubicin (DOX)-loaded 
mesoporous silica nanoparticle (MSN) @ CuS nanohybrid allows for this particle 
to combine photothermal therapy and chemotherapy enhancing therapeutic 
efficacy
93
. To achieve enhanced tumor specificity and controlled drug release, 
hyaluronic acid (HA) was used as a capping agent and conjugated on the MSN 
surface by glutathione (GSH) cleavable disulfide bonds
94
. Hyaluronidases 
(HAase) provide the enzyme-responsive release of HA coating while higher 
concentrations of GSH in tumor cells act as an internal redox stimulus to break 
the disulfide bonds thereby designing a dual-stimuli responsive drug delivery 
system
94
. An intelligent drug delivery system was developed with DOX-loaded 
MSN was first functionalised with folic acid (FA), then coated with a layer of 
gelatin and specked with polyethylene glycols (PEG)
 95
. Tumor tissues are 
reported to have upregulated MMP-2 (a type of matrix metalloproteinase, MMP) 
levels
96, 97
 that hydrolyze the gelatin layer effectively deshielding the PEG 
moieties and removing the protective coating over the MSN cargo drug 
molecules. The FA is now available to facilitate folate-receptor mediated 
uptake
98-100







1.4 RESEARCH OBJECTIVES 
In an attempt to address the need for an effective and efficient anti-breast cancer 
drug delivery system, we synthesized mesoporous silica nanoparticles, 
functionalised the pores with a suitable functional group to increase drug loading 
efficiency, loaded the nanoparticles with the hydrophobic anti-breast cancer drug  
Doxorubicin hydrochloride (DOX), and ran assays to test effects of the 
nanocarriers on the breast cancer cell line, MCF-7.  
 
1.4.1  MSN SYNTHESIS AND SURFACE FUNCTIONALISATION 
We synthesized pristine mesoporous silica nanoparticles (MSN-pristine) using a 
micelle-templating procedure that does not involve any organic solvents or the 
use of alkali as additives
41
. The synthesis procedure involves the formation of 
micelles by the amphiphilic CTAC molecules in water
125
; after the micelles are 
formed, these are coated with silica precursor TEOS. It has been reported that the 
TEOS coated micelles aggregate together to form nuclei which further grow into 
monodisperse nanoparticles
41
. It has been observed that the reaction temperature 
maintained during the nucleation and growth of the nuclei decide the range of 
overall diameter of the nanoparticles synthesized; higher reaction temperatures 
have shown to produce larger particles due  to faster nucleation rates and 
formation of bigger nuclei
41
. The CTAC micelles assembled in water aggregate 
to form nuclei with voids between adjacent nuclei; these voids get filled with the 
silica precursor TEOS. The micelle formation period of 2 h causes some –Si-
OCH2-CH3 groups from TEOS to not undergo complete hydrolyzation and these 
ethoxy groups tend to separate from the hydrophilic water solution aggregating 
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on the reaction solution within the next 24 h
41
. Phosphonate groups were 
functionalised on to the walls of the mesopores in the MSN-pristine by 
introducing the THMP into the working solution 15 min after addition of TEOS; 
this would initiate condensation of the THMP such that the MSN-pristine (now 
MSN-Phos-pristine) would be endowed with a combination of silanol and the 
negatively charged phosphonate groups in its mesopores
101-102
. Post synthesis, the 
nanoparticles were subject to a calcination process at 650⁰C or 6 h, to obtain the 
surfactant free particles denoted MSN and MSN-Phos respectively
41
. To enhance 
the physical aspects of the mesopores on the nanoparticles, these were then 
subject to chemical etching by sodium borohyride (NaBH4) for 2 h
103
. The final 
nanoparticles, now ready to be characterised and tested are denoted MSN-E and 
MSN-Phos-E (E refers to the etching performed on the nanoparticles). 
 
1.4.2  INTERACTION OF DOX WITH MSN 
DOX (pKa 8.2) carries a positive charge at physiological pH and these molecules 
bind electrostatically to the negatively charged MSN surface
101
. Similarly, these 
molecules also bind to the grafted phosphonate groups of the MSN-Phos 
nanoparticles via electrostatic interactions
101
. In both cases, low pH causes the 
electrostatic bond to dissociate releasing the drug molecules from the 
mesoporous nanoparticles however, with the phosphonate functionalisation there 






1.4.3  EFFECT OF UNLOADED MSN ON BREAST CANCER CELLS 
Human breast adenocarcinoma cancer cells, MCF-7 cells and normal human 
foreskin fibroblast cells, BJ cells were exposed to unloaded MSN and unloaded 
MSN-Phos for 24 h to study uptake by these cells, and to observe any effects of 
these nanoparticles on the cells prior to treatment with drug-loaded nanoparticles. 
This is crucial to ensure both cell types take up the nanocarriers, and also to make 
sure these nanoparticles do not have any adverse effects on the normal, healthy 
cells. An important feature of a successful anti-cancer drug delivery system is to 
target the tumor cells without damaging surrounding healthy cells.  
10 
 
2.  MATERIALS AND METHODS 
2.1  MATERIALS 
Cetyltrimethylammonium chloride solution (CTAC, 25wt.% of water), tetraethyl 
orthosilicate (TEOS, 98%), anhydrous sodium acetate (>99%), silicone oil and 
sodium borohydride (NaBH4) were all purchased from Sigma-Aldrich. Glacial 
acetic acid (100%) was purchased from Merck. Doxorubicin hydrochloride 
(DOX) was purchased from Apollo Scientific Limited. 3-(Trihydroxysilyl)propyl 
methylphosphonate monosodium salt solution (THMP, 50wt.% in H2O) was 
purchased from Axil Scientific. Technical grade ethanol (99.86% w 5% methanol) 
was purchased from Aik Moh Paint & Chemicals Pte Ltd and analytical grade 
ethanol from Fischer Chemical. High-glucose Dulbecco's Modified Eagle's 
Medium (DMEM) containing L-glutamine supplemented with 10% FBS and 1% 
antibiotic/antimycotic solution was purchased from PAA Laboratories. Breast 
cancer cells (MCF-7) and Human neonatal foreskin fibroblast cells (BJ) were 
obtained from American Type Culture Collection (ATCC, Manassas, VA). 
Methylthiazolyldiphenyl-tetrazolium (MTT) was purchased from Sigma-Aldrich. 
Dimethyl sulfoxide (HPLC grade, 99%) was purchased from Alfa Aesar. Nitric 
acid (HNO3, 65%) was purchased from Merck. Paraformaldehyde (PFA) and 
Triton X-100 were purchased from Sigma-Aldrich. Phalloidin (CF568 conjugate) 
was purchased from Biotium and Fluorescein isothiocyanate–dextran (FITC-
Dextran) was purchased from Sigma-Aldrich. Phosphate-buffered saline (PBS; 
PAA Laboratories was used to prepare nanoparticle stock suspensions. For all 
experiments, Milli-Q water was used. All chemicals were used without 
purification or modification. 
11 
 
2.2  PREPARATION OF MESOPOROUS SILICA NANOPARTICLES 
MSN were synthesized using the micelle-templating method (Schematic 1) as 
described previously
41
. Typically, 6.24g of CTAC, 53.4g of Milli-Q water and 
0.18g of anhydrous sodium acetate were mixed and stirred at about 500rpm in a 
silicone oil bath at 40°C for 2 h. Thereafter, 4.35ml of TEOS was added into the 
mixture drop-wise under constant stirring. After stirring for 24±3 h, the mixture 
was removed from the oil bath and 25ml of ethanol was added. This mixture was 
centrifuged at 6000rpm for 30 min to isolate the raw product from the mixture. 
The raw product was suspended in ethanol and about 5v/v% of glacial acetic acid 
was added before returning it back into the oil bath with a temperature of 55°C—
15°C higher than before. After constant stirring overnight, raw MSN was 
recovered by centrifugation at 6000rpm for 30 min and washed thrice with 
ethanol. The resultant nanoparticles were freeze dried to obtain MSN-pristine. 






The nanoparticles were functionalised with phosphonate groups using 3-
(Trihydroxysilyl)propyl methylphosphonate monosodium salt solution in a 
procedure wherein after 2 h of CTAC micelle formation was allowed, 3.47ml of 
TEOS was added drop-wise under constant stirring and 15 min later, 0.88ml of 
THMP was added to introduce the phosphonate group (MSN-Phos-pristine)
 101
. 
The subsequent steps were identical to the synthesis of MSN-pristine.  The 
nanoparticles (MSN and MSN-Phos) were then calcinated in a furnace at 650⁰C 
for 6 h to remove any trace of surfactant molecules
41
. MSN-pristine and MSN-
Phos pristine were freeze-dried and placed in a furnace that was then raised to 
said temperature to complete the calcination process. The CTAC-free 
nanoparticles were denoted MSN and MSN-Phos. These were next chemically 
etched using sodium borohydride; 300mg of MSN and MSN-Phos were 
dissolved in 15ml of MQ water and 900mg of NaBH4 powder was slowly added 
to each solution under constant stirring at room temperature for 2 h
103
 (Schematic 
2). Reaction of NaBH4 with water produced NaBO2 and H2, creating an alkaline 
environment that caused reversible Si-O bonds to break and increase effective 
pore size of the nanoparticles
103
. After etching the nanoparticles were washed 
several times with water to remove traces of NaBH4 and were then denoted 




Schematic 2 Proposed reaction sequence of NaBH4 chemical etching to increase MSN pore 
size. In (1) chemical interaction of NaBH4 and H2O produced NaBO2 and H2 creating an alkaline 





2.3  CHARACTERISATION OF NANOPARTICLES 
Nanoparticles were dispersed in ethanol (50µg/ml) and dropped on carbon-coated 
copper grids. Transmission electron microscopy (TEM; JEOL 2010) was utilized 
to determine particle size and morphology. Primary particle size was determined 
by evaluating TEM micrographs of 50 random particles using ImageJ software. 
Dynamic light scattering (DLS; Malvern, UK) was used to measure 
hydrodynamic size and zeta potential. Samples were prepared in PBS and 
DMEM/F12 complete culture medium supplemented with 10% FBS and 1% 
penicillin/streptomycin solution, and sonicated for 5 min before sample 
measurement. The measurement for each sample was done in triplicates and the 
mean values were reported. Pore analysis was performed using NOVA 4200e 
pore size analyzer from Quantachrome Instruments. Freeze-dried MSN samples 
(100-300mg) were degassed overnight at 180°C and the nitrogen adsorption-
desorption isotherms were obtained at 77K (P/Po > 0.9). From the isotherms, 
specific surface area was calculated using the Brunauer-Emmett-Teller (BET) 
method. The Barrett-Joyner-Halanda (BJH) method was used to determine total 
14 
 
pore volume and pore diameter. Surface chemistry of synthesized nanoparticles 
was studied using Fourier Transform Infrared Spectrometer (FTIR-8400S, 
Shimadzu) and X-ray Photoelectron Spectroscopy (Kratos AXIS Ultra from 
Kratos Analytical Limited). 
 
2.4 DOX LOADING OF NANOPARTICLES 
To load DOX into MSN-E and MSN-Phos-E, 4ml of 0.15mg/ml DOX solution 
was prepared and mixed with 0.6mg of the nanoparticle for a 1:1 nanoparticle to 
DOX weight ratio. A control solution without nanoparticle was also prepared. 
Both solutions were left to stir at about 500rpm in the dark for 24 h and 
subsequently centrifuged at 6,000rpm for 15 min.The absorbance value at λab= 
480nm was measured by Epoch UV-Vis Microplate Spectrophotometer from 
Biotek to determine concentration of DOX in the supernatant. The difference in 
absorbance value as compared to the control was utilized to calculate free DOX 
concentration.  Using the Beer-Lambert law, a linear standard curve of R
2
 = 
0.997 was obtained and subsequently used to find concentration from absorbance. 
For the purpose of discussion, the loading efficiency will be computed for a fair 




                            
                   
           




2.5 CELL CYTOTOXICITY ASSAY AND CELL UPTAKE STUDIES 




 in 96-well plates 
(Corning) at standard culture conditions (37⁰C, 5% CO2) in preparation for the 
MTT assay. After 24 h, the cells were treated with varying concentrations of 
MSN-E and MSN-Phos-E (0.025, 0.25, 2.5, 25 and 250µg/ml); the nanoparticle 
suspension prepared in 1× PBS was UV-sterilised for 1 h prior to preparation of 
nanoparticle suspension in DMEM at appropriate concentrations. Standard 
protocol for MTT assay was adopted for measurement of cell viability.  
MSN-E and MSN-Phos-E were tagged with FITC to observe the uptake of 
nanoparticles by the MCF-7 and BJ cells; 100mg of nanoparticles were dissolved 
in 100ml absolute ethanol and set to 80⁰C before adding 5ml of APTES and 
stirring this mixture for 5 h. After 5 h, 25mg/ml of FITC (in ethanol) was added 
drop-wise to this mixture and allowed to stir for 16 h, protected from light. The 
FITC-tagged nanoparticles were then washed several times with ethanol and 
water before freeze drying for further use. MCF-7 and BJ cells were cultured for 




 in 8-well chamber slides (Nunc Lab-Tek II Chamber 
Slide System). These cells were then treated to nanoparticle suspensions prepared 
as described previously, at varying concentrations of 0.025, 2.5 and 250µg/ml for 
24 h. After treatment duration, the cells were washed thrice with PBS and fixed 
using 4% paraformaldehyde in PBS at room temperature for 15 min. The cells 
were then washed thrice with PBS and permeabilized with 0.2% Triton-X 100 in 
PBS at room temperature for 15 min. Next, the cells were washed thrice with 
PBS and unspecific sites were blocked using 2% BSA in 0.1% Triton-X 100 in 
PBS at room temperature for 15 min. The cells were washed thrice with PBS and 
stained with phalloidin prepared in 0.1% BSA in 0.1% Triton-X 100 in PBS, at 
16 
 
room temperature in the dark for 20  min. After washing the phalloidin stained 
cells thrice with PBS, the cells were mounted on glass slides and sealed. Images 
were captured using 20× objective lens on a confocal laser scanning microscope. 
To further analyze the uptake of nanoparticles, MCF-7 and BJ cells were cultured 






 petridishes (Corning) 
in preparation for the ICP-MS analysis. After 24 h, the cells were treated to 
varying concentrations of MSN-E and MSN-Phos-E (0.025, 2.5, and 250 µg/ml); 
the nanoparticle suspensions were prepared as described previously. The cells 
were treated for specific time intervals of 24, 48 and 72 h. After respective 
treatment duration, the cells were prepared for the ICP-MS analysis as per 
standard protocol to measure the levels of silica present in cells.  
 
2.6 GENE EXPRESSION PROFILING AND CELL CYCLE ANALYSIS 
The cells were exposed to the nanoparticles (250µg/ml) for 48 and 72 h. After 
treatment duration, Nucleospin RNA kit (Macherey-Negel, USA) was used 
(according to manufacturer’s instructions) to isolate sample RNA. As per 
manufacturer’s instruction, the collected RNA was converted to first strand 
cDNA using the RevertAid™ H-Minus Reverse Transcriptase kit (Fermentas, 
USA). SsoAdvanced SBYR Green Supermix (Biorad, USA) was used to detect 
differences in gene expression (on a CFX96 system (Biorad, USA)). GAPDH 
expression was used for normalization. The experiment was done in triplicate and 





Table 1 – Sequence of qPCR Primers Screened in the Cell Cycle Analysis 
Genes Forward (Sequence 5’ to 3’) Reverse (Sequence 5’ to 3’) 
BAX GAT GAT TGC CGC CGT GGA CCA ACC ACC CTG GTC TTG 
TNFRSF1A AACGAGTGTGTCTCCTGTAGT GGAGTAGAGCTTGGACTTCCAC 
p21 CCTGTCAATGTCTTGTACCCT GCGTTTGGAGTGGATAGAAATCT 
ATM TTGATCTTGTGCCTTGGCTAC TATGGTGTACGTTCCCCATGT 
CDK1 AAACTACAGGTCAAGTGGTAGCC TCCTGCATAAGCACATCCTGA 
 
The cells were synchronised at G0/G1 check point by growing them in serum-
free DMEM for 48 h prior to nanoparticle treatment (250µg/ml for 48 h). After 
treatment duration, the cells were collected, washed with 1×PBS, and fixed 
overnight in 70% chilled ethanol. The cells were then stained with Tali
®
 Cell 
Cycle solution (Life Technologies, USA) as per supplier’s instruction, and 
analyzed with Tali
®




3. PHYSICAL CHARACTERISATION AND SURFACE CHEMISTRY OF 
NANOPARTICLES 
3.1  MORPHOLOGY AND PARTICLE SIZE STUDIES 
TEM images show that calcinated nanoparticles (MSN and MSN-Phos) and 
etched nanoparticles (MSN-E and MSN-Phos-E) were spherical in shape (Fig. 1 
A-D) with mean sizes of 59.5 ± 4.1, 64.8 ± 3.8 , 55.3 ± 2.7  and 66.9 ± 2.8 nm 
respectively.  
 
Fig. 1 TEM images of (A) MSN, (B) MSN-E, (C) MSN-Phos and (D) MSN-Phos-E were analyzed 
to determine respective primary particle sizes. Data represents mean ± SD, n=3. Scale bar = 
50nm 
 
Hydrodynamic radius for the etched nanoparticles were measured to record the 
actual size of these nanoparticles when introduced to cell cultures. Larger 
hydrodynamic sizes were observed when the nanoparticles were dispersed in 





synthesized on cell cultures, nanoparticle suspensions were prepared in complete 
media. Hence we recorded the hydrodynamic size of the nanoparticles when 
dispersed in DMEM; this is the true size of nanoparticles the cells were exposed 
to. In DMEM the nanoparticles were determined to be 75.3 ± 7.4, 74.8 ± 13.1, 
120.7 ± 12.0 and 352.7 ± 80.3 nm for MSN, MSN-E, MSN-Phos and MSN-Phos-
E respectively.  
 
Fig. 2 Hydrodynamic radius (A) and zeta-potential (B) of the nanoparticles before and after 
etching; the nanoparticles were measured in DMEM complete media. Data represents mean ± 
SD, n=3 
 
Increase in hydrodynamic particle size indicates aggregation in test dispersant 
system; nanoparticles have been reported to readily absorb proteins in serum-
supplemented cell culture media creating a protein corona on the particle surface 
leading to increased diameters
105




 ions in cell 
culture media is also postulated to play a role in nanoparticle aggregation
106-108
. 
The zeta potentials recorded for MSN, MSN-E, MSN-Phos and MSN-Phos-E 
were -22.8 ± 0.6, -20.3 ± 0.7, -31.8 ± 2.0 and -16.9 ± 0.5 mV respectively (Fig. 
2B). Zeta potential is indicative of the surface charge carried by the nanoparticles; 
values recorded less than 30mV indicate reduced electrostatic repulsion between 





3.2  PORE VOLUME AND SURFACE AREA ANALYSIS 
It is the greatly increased surface area of these mesopores of the MSNs that 
enable these nanoparticles to be functionalised to bind cargo molecules. Hence 
BET analysis was conducted to record the average pore diameters and pore 
volumes of the mesopores present on the MSNs, and also record specific surface 
area of the nanoparticles synthesized; this information is important since the 
outer surface of the nanoparticles provide the first platform for absorption of 
cargo molecules, before they can be loaded into the mesopores. Type IV 
hysteresis loops were followed by the nitrogen adsorption-desorption isotherms 
of MSN, MSN-E, MSN-Phos and MSN-Phos-E (Fig. 3 inset) confirming the 
presence of mesopores on the nanoparticle surface
41
. The pore size distribution 
was found to be comparatively unimodal in MSN-Phos and MSN-Phos-E in 
comparison to MSN and MSN-E (Fig. 3).  
 
Fig. 3 Pore size distribution as obtained from BJH Analysis method of (A) MSN, (B) MSN-E, (C) 




It was observed that the average pore diameter of the nanoparticles increased by 
almost 20% in MSN-E and by 5% in MSN-Phos-E (Table 2). The total pore 
volumes of MSN and MSN-E have been recorded to be higher than those of 
MSN-Phos and MSN-Phos-E; this could be attributed to the corresponding 
difference in particle size. Similar difference is also noted in the values of 
specific surface area recorded for the nanoparticles wherein the MSN and MSN-
E have recorded higher values in comparison to MSN-Phos and MSN-Phos-E 
(Table 2). 
 Table 2 – Summary of the Average Pore Diameter, Total Pore Volume and Specific Surface 
Area of Different Nanoparticles 
 
Average Pore Diameter (Å) Total Pore Volume (cm
3
/g) Specific Surface Area (m
2
/g) 
MSN 82.48 0.6842 307.30 
MSN-E 103.97 0.5482 256 
MSN-Phos 188.25 0.2307 85 
MSN-Phos-E 198.24 0.2786 86 
 
 
3.3  MSN SURFACE CHEMISTRY 
FTIR analysis of the nanoparticles proved successful removal of CTAC 
molecules from the samples post calcinations (Fig. 4). Presence of CTAC 
molecules in nanoparticle samples (MSN-pristine and MSN-Phos-pristine) were 
affirmed by the presence of C-H stretching in the region of 2950 and 2850cm
-
1
(Fig. 4, marked by black rectangles)
110
. Peaks in this region were seen to be 
missing in the case of MSN, MSN-E, MSN-Phos and MSN-Phos-E. The 










Si-O-Si symmetric stretching (817cm
-1
) and Si-O bending (460cm
-1
) were found 
in all graphs (Fig. 4) indicating that the silica nanostructure was successfully 
retained post calcinations, etching and functionalisation procedures
111
. The 
presence of absorption peak between 1230 and 1260cm
-1
 (Fig. 4B, marked by 
black oval) showed that phosphonate group was successfully added and chemical 




Fig. 4 FTIR Analysis depicted complete removal of surfactant CTAC molecules from the 
synthesized nanoparticles (Fig.1A and 1B) post-calcination (C-H stretching peaks between 
2950 and 2850cm
-1
 as indicated by the rectangular box); P=O peaks between 1260 and 1230cm
-
1
 in Fig. 1B showed successful phosphonate group functionalisation of the nanoparticles 
 
The presence of the various elements on the nanoparticles was further confirmed 
by their XPS spectra (Fig. 5). The XPS analysis was conducted on MSN-E and 
MSN-Phos-E to determine the presence of Si2p and O1s peaks in both samples, 
and the presence of P2p peak only in the MSN-Phos-E sample (Fig. 5). The 
spectra for Si2p in the range of 99.5 to 105 eV
113
 and the peak for O1s at 533 
eV
114
 show obvious peaks confirming their presence in MSN-E and MSN-Phos-E. 
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Similarly, an obvious peak for P2p, within the range of 130 to 135 eV
115
 can be 
observed in MSN-Phos-E, while the spectra for P2p in MSN-E exhibits 
background noise thereby indicating a complete absence of this element in the 
sample. 
 
Fig. 5 XPS Spectra of MSN-E (A-C) and MSN-Phos-E (D-F) showed presence of Si2p and O1s 




4.  DRUG LOADING EFFICIENCY OF NANOPARTICLES 
DOX and silica nanoparticles (MSN, MSN-E, MSN-Phos, and MSN-Phos-E) 
were stirred at room temperature for 24 h in a 1:1 ratio. After this duration, the 
absorbance reading of the supernatant was recorded and loading efficiencies were 
calculated using standard formula, as described previously. It was observed that 
the etched nanoparticles achieved higher loading efficiencies than those whose 
pore diameters were not modified (Table 3). However, it was also observed that 
numerically, the loading efficiency of phosphonate functionalised particle was 
approximately 47% lower than that of the non-functionalised counterpart.  
 Table 3 – Average Pore Diameters and DOX Loading Efficiencies of Nanoparticles 
Nanoparticle Average Pore Diameter (Å) Loading Efficiency (%) 
MSN 82.4 6.97 
MSN-E 103.9 7.24 
MSN-Phos 188.2 1.06 





This can be explained by a closer examination of the surface characteristics of 
the nanoparticles; due to their larger diameters, MSN-E exhibit a higher specific 
surface area than that of MSN-Phos-E (Table 4). This directly translates to better 
interaction of the MSN-Phos-E nanoparticles with DOX molecules thereby 
carrying higher amount of DOX per unit surface area (Table 4). A record of 0.28 
mg DOX/m
2
 in MSN-E and 0.39 mg DOX/m
2
 in MSN-Phos-E, hence show an 
increased loading capacity of  the functionalised nanoparticles. 
Table 4 – Mass of DOX loaded per unit area of MSN surface 
Nanoparticle 
Mass of DOX Loaded 
(mg) 








MSN-E 0.043 256 0.28 





5. TREATMENT OF CELLS WITH VARIOUS MSN GROUPS 
5.1 CYTOTOXIC EFFECTS OF NANOPARTICLES 
Before testing the effect of DOX-loaded silica nanoparticles on the MCF-7 and 
BJ cells, it was imperative to establish non-toxicity of the empty carrier 
nanovehicles on the normal BJ cells. This biocompatibility of the nanoparticles 
with healthy cells would translate to reduced side-effects from treatment 
process
116
. Hence to study the cytotoxic effects of the nanoparticles, MCF-7 and 
BJ cells were exposed to varying concentrations of MSN-E and MSN-Phos-E 
(2.5, 25 and 250 µg/ml). No discernible change in cell cytotoxicity was observed 
in the BJ cells after 48 h of exposure (Fig. 6B); the cells recorded over 100% cell 
viability indicating uninterrupted growth of cells despite the exposure. However, 
after 72 h, the BJ cells exhibited a concentration-dependent drop in cell viability 
to both MSN-E and MSN-Phos-E treatment (Fig. 6B). 
 The maximum drop in cell viability recorded was 74% (MSN-E exposure) 
and 93.6% (MSN-Phos-E exposure). MCF-7 cells, on the other hand exhibited a 
sharp drop in cell viability after 48 h of nanoparticle treatment (Fig. 6A). Cell 
viability was further reduced to record 51.9% (MSN-E treatment) and 43.4% 
(MSN-Phos-E) treatment after 72 h (Fig. 6A). This shows a concentration 
dependency of both, MCF-7 and BJ cells, to the nanoparticle treatment. Fig. 6C 
and 6D help understand the effect of treatment duration on the cell viability of 
the cells. From these analyses it can be concluded that the nanoparticles have a 
selective cytotoxic effect on the MCF-7 cells in comparison to the BJ cells, and 




Fig. 6 The figures present cell viability of MCF-7 (A) and BJ cells (B) against a concentration 
dependent scenario of nanoparticle treatment and the same for MCF-7 and BJ cells against a 
time dependent scenario (C, D).  Data represents mean ± SD, n=3, *p<0.05 versus control 
 
5.2  QUALITATIVE ANALYSIS OF NANOPARTICLE UPTAKE 
Qualitative analysis of FITC-tagged nanoparticle uptake by the MCF-7 and BJ 
cells was accomplished by confocal microscopy. Both cells types showed the 
presence green signals from the FITC-tagged nanoparticles that coincided with 




Fig. 7 Qualitative study of nanoparticle uptake using confocal laser scanning microscope 
(CLSM) of MCF-7 and BJ cells when treated with 250µg/ml of FITC-tagged MSN-E and MSN-
Phos-E for 24 h showed significant uptake by MCF-7 cells in comparison to a close-to-nil 
uptake shown by BJ cells 
 
Since this does not confirm the physical uptake of nanoparticles by the cells, the 
ICP-MS analysis was performed on both MCF-7 cells and BJ cells, after they 
were exposed to the nanoparticles for 24 h. After treatment duration, MCF-7 
exhibited a concentration dependent uptake of MSN-E and MSN-Phos-E (Fig. 8); 
an increased presence of silica was recorded in these cells with increasing dosage 
of nanoparticle treatment. However, no silica was detected in the BJ cells upon 
24 h of nanoparticle exposure (Fig. 7). 
Hence cytotoxic effects of the MCF-7 cells can be attributed to the uptake of the 
nanoparticles that cause a subsequent intracellular effect on these cells, which are 




Fig. 8 Quantitative study of nanoparticle uptake using ICP-MS upon treatment of MCF-7 and 
BJ cells with varying concentrations of nanoparticles for 24 h showed a concentration 
dependent uptake of nanoparticles by the  MCF-7 cells whereas Si was not detected (ND) in 
the BJ cells indicating poor uptake by these cells. Data represents mean ± SD, n=3 
 
6.  GENE EXPRESSION PROFILING OF MCF-7 AND BJ CELLS 
To understand the seemingly targeted cytotoxic effect of nanoparticles on the 
MCF-7 cells, and to explain the lack of significant cytotoxicity on the normal 
cells, (BJ), levels of specific genes were analysed after 48 and 72 h of 
nanoparticle exposure (Table 1). Any change in the trend of expression of these 
genes was used to understand the behavior of the cells upon exposure to 




Fig. 9 qPCR analysis of MCF-7 and BJ cells treated with 250ug/ml of nanoparticles for 48 h (A) 
versus 72 h (B) indicated that deterioration in cell numbers observed can be attributed to 
irregularities in the cell cycle of the cells. The absence of any significant up-regulation in BAX 
and TNFRSF1A genes indicated no role of apoptosis in causing any cell death  
 
BAX genes encoding proteins that belong to the Bcl-2 family
117
 were mildly 
upregulated in the MCF-7 cells after 48 h and then downregulated after 72 h of 
MCF-7 treatment of nanoparticles. TNFRSF1A genes were also found to be 
downregulated after both, 48 and 72 h of exposure in these cells. The 
downregulation of BAX genes (intrinsic apoptotic pathway) and TNFRSF1A 
(extrinsic apoptotic pathway) was indicative of the absence of the activation of an 
apoptotic pathway caused by the nanoparticles in the MCF-7 cells
117, 118
. 
Similarly, an insignificant upregulation of BAX and TNFRSF1A were observed 
in BJ cells after 48 h of treatment. However, after 72 h of treatment, an 
upregulation of both genes was observed in the BJ cells. Since BJ cell uptake of 
MSN-E and MSN-Phos-E were immeasurably insignificant, compared to MCF-7, 
it can be hypothesized that BJ cells take more than 24 h to take up the 
nanoparticles, and subsequently succumb to the toxicity. ATM genes are 
activated in response to double stranded DNA breaks
119
. A downregulation of 
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this gene in both MCF-7 and BJ cells, after 48 and 72 h of nanoparticle treatment 
showed that the treatment caused no damage to the DNA of the cells. p21, the 
cyclin-dependent kinase inhibitor is known to regulate cell cycle progression at 
G1 and S phase, and plays the role of cellular senescence mediator
120
. A 
consistent upregulation of these genes in the MCF-7 cells irrespective of 
treatment duration signified the nanoparticles play a role in disrupting the natural 
cell cycle progression. A comparative downregulation of the same genes in the 
BJ cells indicated a normal cell cycle progression despite nanoparticle exposure 
over 48 and 72 h. CDK1 genes regulate G1 phase progress and G1 to S phase 
transition, and are also responsible for promoting the G2 to M phase transition
121
. 
Expression of these cells were downregulated in MCF-7 cells after 48 h and 
significantly so, after 72 h of treatment. However, the same genes were shown to 
be upregulated in the BJ cells over both treatment durations; this confirmed the 
hypothesis that the nanoparticles interfere with the normal flow of the cell cycle 
in the MCF-7 cells leading to cell cytotoxicity while no such phenomenon was 
observed in the BJ cells. 
 
7.  NANOPARTICLE EFFECT ON THE CELL CYCLE 
In order to assess the effect of the nanoparticles on the cell cycle of the MCF-7 
and BJ cells, these cells were synchronised in the G0/G1 phase
122, 122
 (Fig. 10A), 
and upon treatment with MSN-E and MSN-Phos-E (250 µg/ml, 48 h) were 
subsequently released to follow the natural stages of the cell cycle. Cells ‘wake 
up’ from their quiescent phase (G0) and move into G1 phase when they commit 





After treatment duration, the cells were analysed to determine the percentage of 
cells present in the various phases of the cell cycle (S, G2 and M phases of DNA 
synthesis, pre-mitosis and mitosis)
124
, and it was determined that, upon treatment 
with MSN-E, 16% of the cells, in excess to that of the control samples were 
retained in the G2/M phase (Fig. 10B). Similarly, 21.4% MCF-7 cells, in excess 
to that of the control samples were retained in the G2/M phase when treated with 
MSN-Phos-E nanoparticles (Fig. 10B). 
This clearly indicated the role of the nanoparticles in causing the cells to digress 
from their natural course of the cell cycle. Having established thus, it was also 
observed that there was a drop in the BJ cell population in the G2/M phase (by 
about 27%), in comparison to the control group, when treated with the 
nanoparticles (Fig. 10B). This could be substantiated by the drop in BJ cell 
viability after 48 h of nanoparticle treatment (Fig. 6B). This however could not 
be linked to the presence of the nanoparticles since the BJ cells did not record 




Fig. 10 MCF-7 and BJ cells were synchronised in the G0/G1 phase (A) and upon treatment with 
MSN-E and MSN-Phos-E for 48 h MCF-7 cells showed an increase in cell population in the 
G2/M phase indicating cell cycle arrest, while a decrease in the same with the BJ cells 
indicated no effect of the nanoparticle treatment on the cell cycle for these cells. Data 
represents mean ± SD, n=3 
34 
 
8.  CONCLUSIONS AND RECOMMENDATIONS 
In this study we synthesized and studied the cytotoxic effects of MSN-E and 
MSN-Phos-E on MCF-7 and BJ cells. MCF-7 cells were derived from human 
mammary gland tissue and to compare the results, we chose BJ cells, a human 
fibroblast cell line that is closer to normal cells than cancer cells, in genetic 
make-up. Our results showed that uptake of the nanoparticles, and subsequent 
cytotoxic effects were observed selectively in MCF-7 cells, with a time 
dependent and concentration dependent tendency. Even the lowest concentration 
of 2.5 µg/ml caused substantial drop in cell viability in MCF-7 cells. In contrast, 
BJ cells showed no detectable uptake of the nanoparticles and exhibited normal 
cell growth over the treatment duration, irrespective of dosage concentration. Our 
results have successfully linked the cytotoxic effects of the nanoparticles to an 
anomaly in the cell cycle progression of MCF-7 cells. 
 
For future work it is recommended to understand the depth of the observed 
selective nature of nanoparticle uptake by MCF-7 cells, and to study the 
mechanism of action of the unloaded nanoparticles on these cells. Also, 
additional cell work may be conducted to verify if the observed phenomenon is 
restricted to MCF-7 cells only or applicable to other strains of breast cancer cells. 
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